Kodiak Sciences (KOD) UBS Global Biopharma Conference 2026 summary
Event summary combining transcript, slides, and related documents.
UBS Global Biopharma Conference 2026 summary
17 Nov, 2026Tarcocimab efficacy and filing
DAYBREAK showed tarcocimab’s vision and fluid-control immediacy at least comparable to EYLEA; after four loading doses, over half of patients reached six-month dosing under stringent retreatment criteria.
Dosing was capped at six months, yet most patients did not meet retreatment criteria by that point; human half-life averaged 20 days, ranging from 10 to 50 days.
A revised formulation combining free and conjugated antibody was credited with supporting the results.
The BLA is being compiled across wet AMD, diabetic retinopathy and retinal vein occlusion, with filing targeted this year and potential approval in 2027.
Management cited an anti-VEGF market of about $15B; EYLEA HD was described as exceeding $8B and Vabysmo as trending above $5B, with expectations of $7B-$8B.
KSI-101 and MESI opportunity
MESI is macular edema associated with ocular inflammation; management estimated an initial U.S. addressable population of ~150,000 and described KSI-101 as a VEGF/IL-6 bispecific.
Phase III PEAK tests 5 mg and 10 mg against sham in severely affected cohorts; six monthly loading doses precede the week-24 endpoint, with mean vision change and 15-letter gain among key measures.
First top-line data are expected before Christmas; management expressed confidence and hopes for mean vision gains above 10 letters, while citing prior phase I/II responder rates above 50% in the sicker-patient group.
The second pivotal is almost fully enrolled, with completion expected this year and data targeted for May/June; a BLA is planned if development supports filing.
Management highlighted immediate fluid control in earlier studies and sees potential across MESI’s diverse inflammatory causes; it contrasted the program with Roche’s narrower anti-IL-6 approach and mixed phase III results.
Pipeline, commercial readiness and financing
KSI-501 had a positive DAYBREAK result in wet AMD and is being evaluated in phase III ALTO, where enrollment and randomization are progressing.
Antibodies are made in the U.S. and conjugates in Switzerland at a co-owned, dedicated facility; management said the facility can provide required commercial supply and is Swissmedic approved.
Management is building commercial capability for retina medicines, citing buy-and-bill potential, attractive pricing and an agile model for a focused U.S. specialty market.
A $70M ATM offering was completed recently; after the PEAK readout, management is considering a traditional financing intended to fund roughly the next 18 months, while emphasizing measured fundraising.
Latest events from Kodiak Sciences
- Zenkuda’s BLA, KSI-101’s PEAK 1 readout and accelerating KSI-501 trials define the near-term milestones.KOD
Jefferies Global Healthcare Conference - DAYBREAK advanced two programs, but losses and financing risks persist.KOD
Q3 2026 - Both drugs matched aflibercept efficacy, enabling 6-month dosing for most patients.KOD
Study result - Net loss hit $123.8M in H1 2026; cash supports operations into 2027, but funding gap remains.KOD
Q2 2026 - Late-stage retinal therapies advance toward key data and BLA filings, targeting approvals by 2027.KOD
Jefferies Global Healthcare Conference 2026 - Q1 2026 saw a $58.2M net loss, strong Phase 3 data, and pivotal trials with funding needs ahead.KOD
Q1 2026 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.KOD
Proxy filing - Shareholders will vote on directors, executive pay, and auditor, with a focus on performance and ESG.KOD
Proxy filing - Pivotal retinal trials advance with improved formulations and strong financial runway.KOD
Goldman Sachs 45th Annual Global Healthcare Conference